Background: Programmed cell death protein-1 (PD1) antibodies are currently the standard treatment for resected high-risk melanoma, yet recurrence rate remains high. Objectives: This real-life observa…

Read more about 'Real-life cohort of patients with resected high-risk melanoma treated by adjuvant anti-PD1 therapy: nearly half of patients underwent recurrences, RFS at 24 months was 64%'...

Posted in Research; Posted 9 months ago 2 Minute(s) to read